Half Year 2024 Roche Holding AG Earnings Call Transcript
Thank you very much, and hello to everyone. Good morning, good afternoon, wherever you are. I'm really looking forward to sharing our half-year results with you today.
Now, let me take you through this slide first. We've had a very strong growth in the first half year. Group sales increased by 8%, excluding COVID by 8 -- by 5%, excluding COVID by 8%. And specifically in the second quarter, as you will see in a second, we had significant growth of 9%, overall. Pharma is growing very well in the base business with 8%, Diagnostics growing 9%.
Both the COVID-19 sales decrease and also the LOE impact, both in line with guidance. The sales decrease in COVID-19 is CHF0.8 billion and also the LOE impact is CHF0.6 billion. There was not much COVID impact in the second quarter. Core operating profit increased by 11%, so significant growth here due to good cost management and shifting resources within the organization. With that, our group core operating margin increased almost 2 percentage points. Our core EPS grew 9% and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |